GIBF2 invests $6m in BioVersys BV100 study launch in China

On September 11, 2024, BioVersys announced a strategic investment from GIBF2 amounting to $6 million to support the launch of the BV100 Phase 1 clinical study in China, scheduled to begin in the first half of 2025. This initiative aims to address the significant medical need posed by Carbapenem-Resistant Acinetobacter baumannii (CRAB) infections, which have seen a dramatic increase in resistance rates in China, rising from 32-41% in 2005 to over 75% in 2018, leading to high mortality rates in intensive care units. The investment aligns with BioVersys' strategy to expand the clinical development of BV100, which has shown promising clinical data. The Phase 1 study will involve healthy volunteers to confirm the safety and pharmacokinetic profile of the drug within the Chinese population. Following this, Chinese patients will be included in the planned global Phase 3 registrational study. GIBF2's extensive network and support for clinical trials in China are expected to facilitate the development process, ensuring that the clinical trials are conducted in top-tier hospitals. The partnership is seen as a significant step towards addressing the urgent need for effective treatments against antibiotic-resistant infections in China. Dr. Marc Gitzinger, CEO of BioVersys, expressed enthusiasm for the partnership, highlighting its potential to expedite the development of BV100. The collaboration is anticipated to make a substantial impact on the Chinese healthcare system, particularly in combating the rising threat of antibiotic resistance.